Elite Pharmaceuticals Files ANDA for Generic Anticoagulant Targeting $26B Market
Summary
Elite Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagulant. This follows an 8-K filed earlier today announcing the same event. The branded product generates $26 billion in annual sales, and no other generics are currently on the market. This filing represents a significant potential revenue stream for Elite Pharmaceuticals, which has a market cap of approximately $370 million. Approval and commercialization will depend on FDA review and navigating existing patents and exclusivities.
At the time of this announcement, ELTP was trading at $0.34 on OTC in the Life Sciences sector, with a market capitalization of approximately $370.5M. The 52-week trading range was $0.33 to $0.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.